Aquestive Therapeutics, Inc.
NASDAQ:AQST · NASDAQ Global Market
+$0.23 today
Vol 2.97M · Avg 1.51M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
248.9%
avg 113.8%
ROIC
-56.0%
avg -59.7%
ROA
-52.2%
avg -60.7%
Analysis
ROE is currently the strongest return metric at 248.9% versus its period average of 113.8%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Daniel Barber | Chief Executive Officer, President & Director | $1.07M | — | 50 | $635,574.00 | 0.64% |
Lori J. Braender BSBA | Corporate Secretary | $695,088.00 | — | 70 | $231,042.00 | 0.23% |
A. Ernest Toth Jr. | Senior VP & CFO | $670,397.00 | — | 67 | $100,000.00 | 0.10% |
Melina T. Cioffi | Senior Vice President of Regulatory Affairs | — | — | 43 | $273,200.00 | 0.28% |
Peter E. Boyd | Senior Vice President of Information Technology & Chief People Officer | — | — | 60 | $281,731.00 | 0.28% |
Thomas A. Zalewski | Chief Legal Officer & Chief Compliance Officer | — | — | 54 | $100,000.00 | 0.10% |
Cassie Jung | Chief Operating Officer | — | — | 47 | $202,246.00 | 0.20% |
Sherry Korczynski | Chief Commercial Officer | — | — | 56 | $238,403.00 | 0.24% |
Robert Charles Arnold | Vice President of Finance, Controller & Assistant Secretary | — | — | — | — | — |
Matthew Greenhawt | Chief Medical Officer | — | — | 52 | $100,000.00 | 0.10% |
Matthew William Davis | Chief Development Officer | — | — | 60 | $100,000.00 | 0.10% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
17
$3.48M
Net Sentiment
$3.48M
Net selling
Most Active
Barber Daniel
5 transactions
1–10 of 17
Analysis
Insiders reported 0 buys worth $0.00 and 17 sells worth $3.48M over the last 12 months. That adds up to net selling of $3.48M. Barber Daniel was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -11.8% | +18.6% (10yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at -11.8% over three years. Forward estimates point to Revenue at +18.6% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Erasca, Inc.
NASDAQ:ERAS
$4.26B
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.42B
Esperion Therapeutics, Inc.
NASDAQ:ESPR
$656.99M
Arvinas, Inc.
NASDAQ:ARVN
$487.78M
Emergent BioSolutions Inc.
NYSE:EBS
$410.19M
Orthofix Medical Inc.
NASDAQ:OFIX
$371.68M
SNDL Inc.
NASDAQ:SNDL
$368.32M
SIGA Technologies, Inc.
NASDAQ:SIGA
$307.90M
Anavex Life Sciences Corp.
NASDAQ:AVXL
$243.26M
DarioHealth Corp.
NASDAQ:DRIO
$50.92M
Who manages AQST?
Aquestive Therapeutics, Inc. (AQST) lists 11 active executives. The top listed executive is Melina T. Cioffi, Senior Vice President of Regulatory Affairs.
Are AQST insiders buying or selling?
Recent insider activity shows net buying of $4.09M.
Explore More
Continue the stock analysis
Jump to another research area for this company.